You should consider shares of Tradeweb Markets Inc. (NASDAQ:TW) and Onconova Therapeutics Inc. (NASDAQ:ONTX) if you are looking for a great stocks to invest in. Starting with the TW shares, which traded at $46.33 at the close of the recent session, dropping -0.81%. On Tuesday, the company’s shares shed -$0.38 from its value which represented in intraday trading. The stock is now -0.04% lower in year-to-date (YTD) trading. TW’s intraday high was $47.10 while its lowest price touched $46.105. The stock’s 52-week high price is $50.48, which means the current price is at -8.22%. In terms of trading activity, the daily trading volume rose to 1078495 against 200-day average trading volume of 704,321 shares.
What are analyst forecasts for Tradeweb Markets Inc. (NASDAQ:TW)?
At a consensus rating of 3.73, TW is trending as a streaking Moderate Buy, as it has been the case a month ago when 10 analysts called it a Moderate Buy. Two months ago, 10 analysts recommended, on average, that TW stock is a Moderate Buy. The Services company’s shares’ overall bearish trend saw it close lower on Tuesday compared to its opening price of $46.78 on the day.
Forecasts for Tradeweb Markets Inc. (NASDAQ:TW) give the stock a fair value for the growth of 9.16% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $51.00, which means the price per share could rise by nearly $4.67. The price range target is between a low of $45.00 and a high of $60.00. The stock would need to gain by about $22.78 to hit the estimated high or 0.73% from its 12-month low.
The consensus among 14 analysts is that it is a good time for one to Overweight in the Tradeweb Markets Inc. 7 analysts rate TW as a Buy, with 0 of 14 analysts rate it as a Sell. 0 have valued the stock as Overweight and 7 have recommended that investors Hold.
Tradeweb Markets Inc. (NASDAQ:TW) Upgrades and Downgrades
In terms of rating changes, Credit Suisse on December 16, 2019, Upgrade Tradeweb Markets Inc. (TW) at Outperform. They believe the stock could reach $54 in the near term. Analysts at Goldman have assigned a Buy rating for the stock in their research note on November 20, 2019 with an estimated price target of $53. Moreover, UBS analysts issued a rating of Buy for the stock on October 21, 2019, giving it a price target of $49 for the next 12 months. On October 01, 2019, the stock earned a Overweight rating due to an analyst call from Barclays, while analysts from BofA/Merrill on September 13, 2019 suggested that the stock is Buy.
Onconova Therapeutics Inc. (NASDAQ:ONTX) adds $0.06 on Tuesday
The ONTX stock has tanked -2.11% year-to-date and is currently trading at $0.37, which is -92.23% below its 52-week high. The company shares gained 19.02% on the day and have risen nearly 265.04% off a low hit. At current levels, Onconova Therapeutics Inc. has a valuation of about $2.20M. As of 02/04/20, this stock has fallen -2.70% during the week and closed at $0.31 in the previous session. However, recent Onconova Therapeutics Inc. stock performance shows that ONTX shares are -22.97% down over the last month, and -29.28% down for the last three months.
Earnings per share (EPS) estimates for the current quarter are -$0.87, with the trailing 12-month share earnings at -$3.63. The ratio is expected to be up by 58.50% for the current year 2019 and 3.40% for next year. But will the ONTX stock surprise in the current quarter results, where the -$0.75 actual EPS reported on 9/29/2019 surprised by -33.90% or was lower by -$0.19 from the estimated -$0.56.
Sales Growth to climb 232.90% for the year
How well will Onconova Therapeutics Inc. perform as a business over the current quarter, year and next 5-year period? Compared to the year-ago quarter, analysts forecast the company to bring in between $60k and $700k in current quarter sales. The consensus estimated for the current quarter is $280k from sales. Forecasts for this fiscal year are between $2.2M and $2.25M and the consensus estimate for sales is at $2.22M. ONTX has its next quarter sales estimates at between $290k and $290k, with the quarter-over-quarter growth estimates at 262.50% and the annual growth forecast for the year at 232.90%.
Who owns shares in Onconova Therapeutics Inc. (ONTX)?
Let’s briefly focus on the share ownership of the Onconova Therapeutics Inc. (NASDAQ:ONTX) stock, where we find that 13.02% of shares are held by institutions.
ONTX Insider Activity
Insider activity can also give a signal in terms of price direction. Looking at Onconova Therapeutics Inc. (ONTX), a total of 703244 shares have been sold by insiders over the last 6 months while 1218760 shares were added in the same time span. On 9/18/2019, by the name 683 Capital Management Llc sold 173332.0 shares worth $377900.0 at the price of $2.18 per share. Filings also show that 683 Capital Management Llc sold a total of 118726.0 shares on 9/18/2019 valued at $258800.0. Since the last insider activity, the company’s share price has dropped -78.70%.